<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01870427</url>
  </required_header>
  <id_info>
    <org_study_id>NCRVA-2013-Newton-4-01</org_study_id>
    <nct_id>NCT01870427</nct_id>
  </id_info>
  <brief_title>NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions</brief_title>
  <acronym>NEWTON</acronym>
  <official_title>NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern California Retina Vitreous Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northern California Retina Vitreous Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effect of Intravitreal Aflibercept Injection&#xD;
      (IAI) on previously treated Central Retinal Vein Occlusions (CRVOs) with other Anti-VEGF&#xD;
      agents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, open-label, single-center, nonrandomized, investigator-sponsored clinical&#xD;
      study seeks to investigate the visual outcomes of a treat and extend dosing regimen of&#xD;
      intravitreal aflibercept injection for macular edema following CRVO. All patients will&#xD;
      receive IAI 2 mg at baseline and Week 4. If the pre-defined extension criteria are met at the&#xD;
      4-week visit, and at any follow up visit, the patient will receive a mandated treatment, and&#xD;
      the next visit will be extended by two weeks. If the extension criteria are not met on a&#xD;
      follow-up visit, the treatment interval will be continued to be reduced by 1 week. If&#xD;
      criteria are still not met despite treatment at the reduced interval, treatment will be&#xD;
      administered as usual and follow up interval will continue to be reduced by 1 week until the&#xD;
      criteria are met or a 4-week interval is reached. Treatment of IAI is rendered at every&#xD;
      visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Intravitreal Aflibercept on Treatment Interval</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Mean number of weeks between each injection where there is no macular edema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Mean change in EDTRS BCVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Mean change in Central Subfoveal Thickness by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Incidence and severity of ocular and systemic AE's</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatments</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Mean number of Intravitreal Injections</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Macular Edema With Central Retinal Vein Occlusions</condition>
  <arm_group>
    <arm_group_label>Aflibercept (2.0 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal Aflibercept (2.0 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept (2.0 mg)</intervention_name>
    <description>Intravitreal Aflibercept (2.0 mg)</description>
    <arm_group_label>Aflibercept (2.0 mg)</arm_group_label>
    <other_name>Eylea</other_name>
    <other_name>VEGF Trap-EYE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 and above with documented history of center-involved macular edema&#xD;
             secondary to CRVO.&#xD;
&#xD;
          -  Patients must have received treatment for at least 6 months before baseline, with 3&#xD;
             initial loading doses, and evidence of recurrence of edema when extended beyond 4&#xD;
             weeks.&#xD;
&#xD;
          -  Protocol refracted ETDRS BCVA of 20/25 to 20/320 (73-24 letters).&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study-related procedures.&#xD;
&#xD;
          -  Provide signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior panretinal or macular laser photocoagulation&#xD;
&#xD;
          -  Previous use of intraocular corticosteroids or use of periocular corticosteroids&#xD;
             within the 3 months prior to day 1&#xD;
&#xD;
          -  Prior treatment with systemic anti-VEGF agents&#xD;
&#xD;
          -  Presence of iris neovascularization&#xD;
&#xD;
          -  Vitreous hemorrhage in the Study Eye&#xD;
&#xD;
          -  Traction retinal detachment, or preretinal fibrosis involving the macula&#xD;
&#xD;
          -  Diabetic macular edema or diabetic retinopathy, defined as eyes of diabetic patients&#xD;
             with more than 1 microaneurysm outside the area of the vein occlusion.&#xD;
&#xD;
          -  Infectious blepharitis, keratitis, scleritis, or conjunctivitis.&#xD;
&#xD;
          -  Active intraocular inflammation (grade trace or above) in the study eye, or history of&#xD;
             idiopathic or autoimmune-associated uveitis in either eye.&#xD;
&#xD;
          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure equal or&#xD;
             greater than 30mmHg despite treatment with anti-glaucoma medication)&#xD;
&#xD;
          -  Concurrent eye disease in the study eye that could compromise visual acuity (e.g.&#xD;
             advanced glaucoma, age-related macular degeneration, etc)&#xD;
&#xD;
          -  Any concurrent intraocular condition in the study eye (e.g. glaucoma) that, in the&#xD;
             opinion of the investigator, could either require medical or surgical intervention&#xD;
             during the 52 weeks study period to prevent or treat visual loss that might result&#xD;
             from that condition.&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Sexually active men* or women of childbearing potential** who are unwilling to&#xD;
             practice adequate contraception during the study (adequate contraceptive measures&#xD;
             include stable use of oral contraceptives or other prescription pharmaceutical&#xD;
             contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device&#xD;
             [IUD]; bilateral tubal ligation; vasectomy; condom plus, contraceptive sponge, foam or&#xD;
             jelly, or diaphragm) *Contraception is not required for men with documented vasectomy.&#xD;
             **Postmenopausal women must be amenorrheic for at least 12 months in order not to be&#xD;
             considered of child bearing potential. Pregnancy testing and contraception are not&#xD;
             required for women with documented hysterectomy or tubal ligation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rahul N Khurana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern California Retina Vitreous Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013 Mar;155(3):429-437.e7. doi: 10.1016/j.ajo.2012.09.026. Epub 2012 Dec 4.</citation>
    <PMID>23218699</PMID>
  </reference>
  <reference>
    <citation>Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X, Beckmann K, Haller JA. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012 May;119(5):1024-32. doi: 10.1016/j.ophtha.2012.01.042. Epub 2012 Mar 21. Erratum in: Ophthalmology. 2012 Nov;119(11):2204.</citation>
    <PMID>22440275</PMID>
  </reference>
  <reference>
    <citation>Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012 Apr;119(4):802-9. doi: 10.1016/j.ophtha.2011.12.005. Epub 2012 Feb 1.</citation>
    <PMID>22301066</PMID>
  </reference>
  <reference>
    <citation>Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011 Oct;118(10):2041-9. doi: 10.1016/j.ophtha.2011.02.038. Epub 2011 Jun 29.</citation>
    <PMID>21715011</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>May 25, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northern California Retina Vitreous Associates</investigator_affiliation>
    <investigator_full_name>Rahul Khurana, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Macular Edema</keyword>
  <keyword>Central Retinal Vein Occlusion</keyword>
  <keyword>CRVO</keyword>
  <keyword>Aflibercept</keyword>
  <keyword>VEGF Trap-Eye</keyword>
  <keyword>Eylea</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

